A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

BACKGROUND: Prognosis of pancreatic cancer is poor with a 5-year survival rate of only 7%. Although several new chemotherapy treatments have shown promising results, all patients will eventually progress, and we need to develop newer chemotherapy treatments to improve response rates and overall surv...

Fuld beskrivelse

Na minha lista:

Bibliografiske detaljer
Udgivet i:	BMC Cancer
Main Authors:	Hirooka, Yoshiki, Kasuya, Hideki, Ishikawa, Takuya, Kawashima, Hiroki, Ohno, Eizaburo, Villalobos, Itzel B., Naoe, Yoshinori, Ichinose, Toru, Koyama, Nobuto, Tanaka, Maki, Kodera, Yasuhiro, Goto, Hidemi
Format:	Artigo
Sprog:	Inglês
Udgivet:	BioMed Central 2018
Fag:	Research Article
Online adgang:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5970460/ https://ncbi.nlm.nih.gov/pubmed/29801474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4453-z
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Lignende værker